Dan T. Vogl, MD, MSCE, discusses the mechanism of action of modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.
Dan T. Vogl, MD, MSCE, of Abramson Cancer Center, associate professor of medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, discusses the mechanism of action of modakafusp alfa (previously TAK-573) for the treatment of patients with relapsed or refractory multiple myeloma.
Modakafusp alfa is a novel immune-targeted attenuated cytokine that is designed to deliver interferon-alpha to CD38-expressing cells via a CD38-targeting IgG4 monoclonal antibody.
The targeted interferon therapy was evaluated in a first-in-human, open-label, phase 1 trial (NCT03215030) to determine the safety, tolerability, and efficacy of modakafusp alfa as single agent as well as in combination with dexamethasone in patients with relapsed/refractory multiple myeloma.
Patients enrolled in the study are aged 18 years and older with relapsed/refractory multiple myeloma. The 3-part study also included a 30 patient dose-expansion cohort.
0:10 | Modakafusp alfa, which we are calling moda, is a targeted interferon therapy. It is an immunocytokine fusion protein combining attenuated interferon alpha-2b molecules attached to an anti-CD38 antibody backbone. So, it is a way of delivering interferon alpha signaling directly to CD38-expressing cells, which includes both myeloma plasma cells in a variety of cells in the immune system.
0:39 | We are presenting the final results from our phase 1 trial of modakafusp alfa comprising a total of 100 patients treated at a variety of doses, including a 30 patient expansion cohort at 1 of the 2 doses that we think would be a recommended phase 2 dose of 1.5 mg per kg IV every 4 weeks. We are really excited about the results of the trial. We are seeing an exciting response rate of 43% at our recommended phase 2 dose, including responses in patients who are refractory to prior anti-CD38 monoclonal antibodies, and responses in heavily refractory patients, including patients refractory to anti-BCMA therapies.